Yuriy Abramov is a Senior Principal Scientist at Pfizer Inc. with 15 years of experience in computational sciences in Drug Discovery and Development. He has a proven track record for developing new ideas and approaches from the concept stage to successful implementation. His current interests include but not limited to computational pharmaceutical solid state chemistry.
Thomas Passananti Professor and Vice Chair for Research, Department of Pharmacology
Thomas Passananti Professor, Department of Biochemistry & Molecular Biology
Scientific Program: Experimental Therapeutics
Dr. Dokholyan is the Vice Chair for Research, Departments of Pharmacology and Biochemistry & Molecular Biology at Penn State College of Medicine. The mission of his lab is to develop and apply integrated computational and experimental strategies to understand, sense and control misfolded proteins in order to uncover the etiologies of human neurodegenerative diseases and develop therapeutics to fight them.
Sean has over 23 years experience in pharmaceutical drug discovery. He graduated from the University of Aberdeen; receiving his M.Sc., Ph.D. in Clinical Pharmacology and D.Sc. in Science. He is currently Founder and CEO of Collaborations Pharmaceuticals, Inc. which is focused on using machine learning approaches for rare and neglected disease drug discovery.
Development and application of cheminformatics methods to characterize, visualize, model and predict dynamic protein-ligand interactions. We focus on kinase-inhibitor complexes (cancer treatment) and HLA-drug complexes (adverse drug reactions).
Peter Ho is a senior advisor to M4K Pharma. Previously, he served as Senior VP of the Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline, Chief Medical Officer at Epizyme Inc, and co-Founder and President of BeiGene, Ltd. He has been directly responsible for the first-time-in-human dosing of 18 anticancer agents and has overseen the development of over 60 hematology and oncology compounds. His work has contributed to eleven NCE or biologics approvals to date: Gleevec®; Arranon®; Tykerb®; Promacta®; Votrient®; Synribo®; Tafinlar®; Mekinist®; Sylvant®; and Rydap®, and Tazverik®.
Dr Jeffries is a mathematician with expertise in predictive machine learning applied to schizophrenia and other psychiatric and neurological disorders. Methods he invented have been recently applied to clinical datasets, yielding novel approaches to address reproducible classification and to avoid overfitting. In particular, he invented an algorithm that, compared to the powerful and widely used LASSO method, selects smaller sets of biomarkers, yields superior classification, and displays greater weight stability. It has appeared in four publications. His target is not individually informative biomarkers, but identification of networks – all passing permutation testing better than LASSO – and thus in some cases yielding statistically significant data interpretation in place of mere trends with LASSO.
Aside from an adjunct appointment with CBMC, Dr. Jeffries is a bioinformatics scientist with The Renaissance Computing Institute of the University of North Carolina at Chapel Hill.
Collaborating since 2005 with UNC psychiatrist Diana Perkins, he has generated a UNC patent on separation of blood stem cells and a provisional patent for use in schizophrenia of an anti-oxidant drug currently indicated for multiple sclerosis. His portfolio includes 121 issued patents, mainly from work with IBM’s Microelectronics Division. Recent biochemical and medical publications are listed in PubMed. He is an Overseas Fellow of the Royal Society of Medicine.
Dr. Jian Jin is an internationally recognized medicinal chemist with more than 20 years of experience in small-molecule drug discovery. He is currently the Mount Sinai Endowed Professor in Therapeutics Discovery, Professor in Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, and the Director of the Mount Sinai Center for Therapeutics Discovery at Icahn School of Medicine at Mount Sinai. Dr. Jin is also a Co-Leader of the Cancer Clinical Investigation Program in The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai. Dr. Jin’s laboratory is a leader in discovering selective inhibitors of histone methyltransferases, novel degraders targeting oncogenic proteins, and biased ligands of G protein-coupled receptors.
Dr. Jin received a Bachelor’s of Science degree in chemistry from University of Science and Technology of China in 1991 and a PhD in organic chemistry from the Pennsylvania State University in 1997. After completing a post-doctoral training at the Ohio State University, Dr. Jin joined GlaxoSmithKline as a medicinal chemist in 1998 and had been a manager of medicinal chemistry from 2003 to 2008. In 2008, Dr. Jin joined the Division of Chemical Biology and Medicinal Chemistry at the University of North Carolina at Chapel Hill (UNC) as an Associate Professor. He had also served as an Associate Director of Medicinal Chemistry in the Center for Integrative Chemical Biology and Drug Discovery at UNC from 2008 to 2014. Dr. Jin was recruited to Icahn School of Medicine at Mount Sinai as a professor with tenure in 2014. Dr. Jin has published close to 200 peer-reviewed papers and delivered >100 invited talks. He is also an inventor of >60 issued U.S. patents and published international patent applications.
Dr. John’s is the Director of Medicinal Chemistry, GlaxoSmithKline and was awarded the “Hero of Chemistry” award from the American Chemical Society for his work in creating the drug Tivicay (dolutegravir), which is now widely used worldwide to treat HIV infection. He is now leading the GSK team that is collaborating with the UNC-Chapel Hill HIV Cure Center. That research is focused on creating a drug that will cure HIV, not just suppress the symptoms.
Dr. Kyoko Nakagawa-Goto is an associate professor in the School of Pharmaceutical Sciences, Kanazawa University, Japan. Her research group has been working in the field of organic, natural products, and medicinal chemistry focused on targeting antitumor and antivirus.
David E. Nichols PhD previously held the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology and in addition was a Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology at the Purdue University College of Pharmacy. He was continuously funded by the NIH for nearly three decades and served on numerous government review panels. His two principal research areas focused on drugs that affect serotonin and dopamine transmission in the CNS. He began medicinal chemistry research on hallucinogens in 1969 and has been internationally recognized as a top expert on the medicinal chemistry of psychedelics (hallucinogens). He has published more than 300 scientific articles, book chapters, and monographs. In 1993 he founded the Heffter Research Institute, which has supported and funded clinical research with psilocybin and led the so-called “renaissance in psychedelic research.”
Dr. Pedersen is a structural biologist at the NIEHS/NIH with research focuses on heparan sulfate biosynthesis and interactions, sulfotransferases and DNA repair.
Dr. Tang is a collaborating member from ViiV Healthcare with the UNC-Chapel Hill HIV Cure Center. His research is focused on discovering novel HIV latency reversal agents with better tolerability and exploring new ways to clear the latent T cells upon activation and viral particles.
Dr. Lan Xie has more than 35 years of experience in the field of medicinal chemistry. Her research focuses on discovery and development of new anti-HIV and antitumor drugs, including design, synthesis, lead optimization, and druggability assessments.
Dr. Zheng is an Associate Professor & the Assistant Chair of Department of Pharmaceutical Sciences and a principle investigator of the BRITE Institute at North Carolina Central University. His lab focuses on the development and application of Computer Aided Drug Design (CADD) Tools to various drug discovery projects. He is also developing and applying artificial intelligence (AI) technologies to pharmaceutical data analysis for drug repurposing in cancer, neurodegenerative and rare diseases.